These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 27918765)

  • 1. Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid.
    Shahnawaz M; Tokuda T; Waragai M; Mendez N; Ishii R; Trenkwalder C; Mollenhauer B; Soto C
    JAMA Neurol; 2017 Feb; 74(2):163-172. PubMed ID: 27918765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.
    Singer W; Schmeichel AM; Shahnawaz M; Schmelzer JD; Boeve BF; Sletten DM; Gehrking TL; Gehrking JA; Olson AD; Savica R; Suarez MD; Soto C; Low PA
    Ann Neurol; 2020 Sep; 88(3):503-512. PubMed ID: 32557811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid.
    Concha-Marambio L; Pritzkow S; Shahnawaz M; Farris CM; Soto C
    Nat Protoc; 2023 Apr; 18(4):1179-1196. PubMed ID: 36653527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.
    Shi M; Bradner J; Hancock AM; Chung KA; Quinn JF; Peskind ER; Galasko D; Jankovic J; Zabetian CP; Kim HM; Leverenz JB; Montine TJ; Ginghina C; Kang UJ; Cain KC; Wang Y; Aasly J; Goldstein D; Zhang J
    Ann Neurol; 2011 Mar; 69(3):570-80. PubMed ID: 21400565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accurate Detection of α-Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort.
    Concha-Marambio L; Weber S; Farris CM; Dakna M; Lang E; Wicke T; Ma Y; Starke M; Ebentheuer J; Sixel-Döring F; Muntean ML; Schade S; Trenkwalder C; Soto C; Mollenhauer B
    Mov Disord; 2023 Apr; 38(4):567-578. PubMed ID: 36781413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure.
    Singer W; Schmeichel AM; Shahnawaz M; Schmelzer JD; Sletten DM; Gehrking TL; Gehrking JA; Olson AD; Suarez MD; Misra PP; Soto C; Low PA
    Ann Neurol; 2021 Jun; 89(6):1212-1220. PubMed ID: 33881777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of α-synuclein seeding amplification assays in α-synucleinopathies: A systematic review and meta-analysis.
    Yoo D; Bang JI; Ahn C; Nyaga VN; Kim YE; Kang MJ; Ahn TB
    Parkinsonism Relat Disord; 2022 Nov; 104():99-109. PubMed ID: 36289019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC.
    Groveman BR; Orrù CD; Hughson AG; Raymond LD; Zanusso G; Ghetti B; Campbell KJ; Safar J; Galasko D; Caughey B
    Acta Neuropathol Commun; 2018 Feb; 6(1):7. PubMed ID: 29422107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discriminating α-synuclein strains in Parkinson's disease and multiple system atrophy.
    Shahnawaz M; Mukherjee A; Pritzkow S; Mendez N; Rabadia P; Liu X; Hu B; Schmeichel A; Singer W; Wu G; Tsai AL; Shirani H; Nilsson KPR; Low PA; Soto C
    Nature; 2020 Feb; 578(7794):273-277. PubMed ID: 32025029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
    Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies.
    Oeckl P; Metzger F; Nagl M; von Arnim CA; Halbgebauer S; Steinacker P; Ludolph AC; Otto M
    Mol Cell Proteomics; 2016 Oct; 15(10):3126-3138. PubMed ID: 27507836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of Misfolded α-Synuclein Aggregates in Cerebrospinal Fluid by the Protein Misfolding Cyclic Amplification Platform.
    Concha-Marambio L; Shahnawaz M; Soto C
    Methods Mol Biol; 2019; 1948():35-44. PubMed ID: 30771168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies.
    Bargar C; Wang W; Gunzler SA; LeFevre A; Wang Z; Lerner AJ; Singh N; Tatsuoka C; Appleby B; Zhu X; Xu R; Haroutunian V; Zou WQ; Ma J; Chen SG
    Acta Neuropathol Commun; 2021 Apr; 9(1):62. PubMed ID: 33827706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease.
    Russo MJ; Orru CD; Concha-Marambio L; Giaisi S; Groveman BR; Farris CM; Holguin B; Hughson AG; LaFontant DE; Caspell-Garcia C; Coffey CS; Mollon J; Hutten SJ; Merchant K; Heym RG; Soto C; Caughey B; Kang UJ
    Acta Neuropathol Commun; 2021 Nov; 9(1):179. PubMed ID: 34742348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF biomarkers and clinical progression of Parkinson disease.
    Hall S; Surova Y; Öhrfelt A; Zetterberg H; Lindqvist D; Hansson O
    Neurology; 2015 Jan; 84(1):57-63. PubMed ID: 25411441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage.
    Majbour N; Aasly J; Abdi I; Ghanem S; Erskine D; van de Berg W; El-Agnaf O
    Neurology; 2022 Nov; 99(21):e2417-e2427. PubMed ID: 36096686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.